Evaluating the safety and effectiveness of Zepzelca™ injection for small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and efficacy of Zepzelca™ injection in real-world clinical practice for patients with metastatic small cell lung cancer (SCLC) who have not responded to first-line platinum-based chemotherapy. The study will also investigate identified risks and gaps in information related to risk management plans. Participants will provide consent for the collection and use of their personal information after being informed about the study's objectives and methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who voluntarily provide written consent for personal information collection and utilization after receiving an explanation about the objective and methods of the study
* Patients who have received or are scheduled to receive Zepzelca™ inj., according to domestic approval indications
* Patients with metastatic SCLC who have failed first-line platinum-based chemotherapy

Exclusion Criteria:

* Patients with no prior history of platinum-based anticancer chemotherapy for cancer treatment
* Patients with a history of hypersensitivity reactions to this drug or its components
* Pregnant, potentially pregnant, or lactating women
* Patients currently participating in another clinical trial (drug or medical device) or planning to participate in another clinical trial during the study period (except for non-interventional clinical studies or cases where the clinical trial drug administration has ended and only follow-up is remaining)
* Patients who are judged by the principle Investigator or sub-Investigator to be ineligible to participate in the study.

Where it's running

• Seoul National University Boramae Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Shinyoung Oh
• Email: syoh@boryung.co.kr
• Phone: +82-2-708-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Using a new PFD3 PET tracer to find and stage small cell lung cancer

  This test will try a new PET tracer called PFD3 in adults with small cell lung cancer to see if it detects tumors and stages disease more accurately than standard FDG PET/CT.

  Recruiting Phase 1/2 Peking University First Hospital · Beijing, Beijing Municipality · NCT07508852

• HLX3901 for advanced small cell lung cancer or neuroendocrine carcinoma

  This study will test whether IV HLX3901 is safe and how the body processes it in adults with advanced small cell lung cancer or neuroendocrine carcinoma who have progressed after platinum-based therapy.

  Recruiting Phase 1 Shanghai Henlius Biotech · Beijing and 1 other locations · NCT07416695

• Golidocitinib plus PD-1 inhibitor maintenance for previously untreated extensive-stage small cell lung cancer

  This trial will see if adding golidocitinib to PD-1 inhibitor maintenance helps people with previously untreated extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing and 1 other locations · NCT07110103

• Cognitive screening for lung cancer patients

  This study is trying to see if lung cancer and its treatments affect thinking skills in patients during their first year after diagnosis.

  Recruiting European Institute of Oncology · Milan · NCT06727370

• Testing TUB-030 for advanced solid tumors

  This study is testing a new drug called TUB-030 to see if it can safely help adults with advanced solid tumors, especially those with head and neck cancer or non-small cell lung cancer.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · New Haven, Connecticut and 19 other locations · NCT06657222

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.